FDA Says Medicare Policy on ESAs "Consistent With Available Data"

From The Cancer Letter, Oct. 19, 2007:

Plunging into the Congressional debate over proper use of erythropoiesis-stimulating agents in oncology, FDA officials said that the controversial new Medicare policy restricting coverage of these drugs is "generally consistent with the available data and the published scientific literature."
_____
tags: policy issues